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Abstract 16 
When assessing the environmental exposure of active pharmaceutical ingredients (APIs), the 17 
mass contributed from over the counter (OTC) sales and topical formats are typically not 18 
included. A data gathering exercise was performed to obtain UK per capita API usage for 19 
ibuprofen, diclofenac and ranitidine, combining all relevant sources to assess their relative 20 
importance as inputs. The calculated releases to wastewater compared well with influent 21 
concentrations measured at several UK wastewater treatment plants (WWTPs), although 22 
consistent overestimation was observed, attributed to a number of factors, including in-sewer 23 
removal. OTC sales were found to make up a large proportion of the mass of ibuprofen (76%) 24 
and diclofenac (35%) consumed and are important to include in exposure assessment. Product 25 
format should also be considered, as compared to oral applications, topical applications of 26 
ibuprofen and diclofenac contribute disproportionately to wastewater loadings per unit mass 27 
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used (43% and 99% of the total mass released, respectively). Options to reduce releases from 28 
these sources are highlighted. Releases of all three APIs did not vary significantly over time, 29 
but variation in releases from different regions in the UK were significant. The importance of 30 
several under-addressed aspects of API exposure assessment are therefore highlighted.     31 
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1. INTRODUCTION 32 
Active pharmaceutical ingredients (APIs) are vital in the treatment of many ailments in a 33 
medical setting and are a cornerstone of modern-day life. Increasingly, the use of 34 
pharmaceuticals has been put in the hands of the consumer, allowing easier access to relief 35 
from common ailments via self-care.1 Over the counter (OTC) products containing 36 
pharmaceuticals aiding in the relief of cold or flu-like symptoms, pain or heartburn are 37 
particularly commonplace and are a significant portion of the market. Along with the benefits 38 
to consumers of immediate access to symptom relief, the burden on healthcare systems is 39 
reduced and the OTC market has and continues to grow.2 An inevitable downside to the 40 
improved access to self-care is the uncontrolled consumption and excretion of pharmaceuticals 41 
to wastewater and the environment, with APIs being detected around the globe.3 Within Europe, 42 
in acknowledgement of this, and in addition to other water quality issues, the European Union 43 
produced the Water Framework Directive (WFD)4 and Priority Substance Directives.5,6 44 
Combined, these directives provide a framework to identify substances that potentially pose a 45 
risk to surface waters, to define environmental quality standards (EQSs) for those deemed to, 46 
and to provide a legal basis with which member state compliance with these EQSs can be 47 
ensured. Member states, where concentrations in surface waters exceed EQSs, may take a 48 
number of different actions to reduce the concentrations of priority substances in surface waters. 49 
These actions depend on various factors, including the socioeconomic value of the substance.  50 
Waste water treatment plants (WWTPs) have been identified as important sources of used 51 
substances, with increasing pressure put on owners to identify source inputs and to reduce 52 
effluent concentrations.7 The Chemicals Investigation Programme (CIP) is a project being 53 
undertaken by UK Water Utility providers, coordinated by United Kingdom Water Industry 54 
Research (UKWIR) in response to these pressures.8 The implementation of this project, 55 
including the substance selection criteria, and some of its results, have been described in 56 
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previous publications.9–12 The project consists of three parts, CIP1-C1 – investigations to assess 57 
risk from chemicals discharged to receiving waters, CIP1-C2 – Investigations to assess 58 
WWTPs performance, CIP1-C3 – Urban sources of chemicals to sewer investigations.9 As part 59 
of the CIP2 project, influent concentrations for ibuprofen, diclofenac and ranitidine were 60 
recorded alongside 16 other APIs across 45 WWTPs between 2015-2017.  61 
The investigation of sources of APIs release to the environment is an important facet in 62 
ensuring no environmental harm comes from their use. Assessing the risk these sources are 63 
likely to have on their surrounding environments requires the determination of their subsequent 64 
concentration in surface waters and other environmental compartments. In this vein, models 65 
such as ePiE (exposure to Pharmaceuticals in the Environment) have been developed as part of 66 
the wider Innovative Medicines Initiative iPiE work scheme for the intelligent assessment of 67 
pharmaceuticals in the environment.13 Whilst not necessarily developed for assessing 68 
pharmaceuticals specifically, other exposure models exist such as PhATE, iSTREEM, 69 
GWAVA, GREAT-ER and LF2000-WQX.14–19  70 
As summarised by Kapo et al. (2017),20 various studies have highlighted the importance of 71 
considering the pre-WWTP sewer system when estimating chemical exposure to the 72 
environment (including for APIs)21, failure to do so leading to the overestimation of WWTP 73 
influent concentrations for certain chemicals. GREAT-ER and LF2000-WQX both consider 74 
the removal of substances during sewer transport.14–16 However, currently, ePiE, PhATE, 75 
iSTREEM and GWAVA do not explicitly consider in-sewer removal.13,17–19 It is important to 76 
consider the impact, or lack-thereof, that in-sewer removal might have on the inputs to these 77 
models when performing an exposure assessment.  78 
OTC sales are a significant route by which certain APIs might be purchased and consumed. 79 
Burns et al. (2017)22 highlighted the need for new approaches that incorporate OTC sales. The 80 
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lack of consideration of all routes of consumption identified as the reason that predicted 81 
environmental concentrations (PECs) underpredict measured environmental concentrations 82 
(MECs) in their own study And other studies such as Carballa et al. (2008)23 and Oosterhuis et 83 
al. (2013)24 only considering prescription data. A running theme is that OTC data is less 84 
accessible than prescription data.25–30 Indeed, a few studies have incorporated aspects of OTC 85 
data into the prediction of environmental releases, however, the methods to obtain and use 86 
these data are country specific and no study that has considered OTC sales has also considered 87 
the topical applications of the APIs being investigated.24,31–33 For example, He et al. (2020)31 88 
analysed data on OTC sales in Japan using data gathered by the ministry of Health Labour and 89 
Welfare, however only calculated emissions using the excretion factor of orally taken ibuprofen 90 
and diclofenac, not considering unabsorbed topically applied product. Azuma et al. (2015)32 91 
used a handbook detailing pharmaceutical sales in Japan to include OTC sales of diclofenac 92 
(although the other APIs investigated were prescription usage only), however this data was 93 
limited to pharmaceuticals sold by major pharmaceutical companies only and did not account 94 
for the volume of pharmaceuticals sold as generics by smaller companies. In addition, the use 95 
of topical products and the variation in absorption does not appear to have been considered in 96 
their methods either. Unfortunately, the methods to incorporate OTC data used are not 97 
applicable outside of Japan and in many countries, for example the UK, government agencies 98 
do not track data on over the counter sales.  99 
Whilst not applicable for all APIs, topical formulations are also overlooked and the 100 
consideration of their different pathway to wastewater missed. There are a number of examples 101 
of this in the recent literature 23,24,31–33  despite the fact that a large proportion of topical 102 
application is not absorbed and metabolised by the human body.34 103 
This study presents a holistic approach, investigating the significance of OTC and topical 104 
applications in addition to temporal and subnational variation in use. To the authors knowledge, 105 
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no studies in the existing literature have investigated all these aspects together, and consider 106 
topical applications. In the present study, we assess the importance of including OTC sales and 107 
topical applications, as well as any potential removal en route to WWTPs, when performing 108 
environmental exposure assessment. Due to practical time limitations, and the labour-intensive 109 
process involved in making use of the OTC dataset, a subset of pharmaceuticals was chosen as 110 
a proof of concept for this study, covering the main routes of emission and acquisition in the 111 
UK, namely, ibuprofen (available via prescription, OTC, both oral and topical), diclofenac 112 
(prescription, oral and topical, OTC topical), and ranitidine (prescription and OTC, oral only). 113 
All three APIs were identified by Comber et al. (2018)11 as APIs  having a high potential to be 114 
considered as candidate priority substances under the WFD. Since that publication, both 115 
diclofenac and ibuprofen are currently being considered by the EU commission as candidates 116 
for the priority substances list under the WFD 35. The mass released to individual WWTPs 117 
based on these data is calculated and compared with influent concentrations measured during 118 
the CIP1-C2 project to validate the approach taken. Differences in regional and temporal 119 
releases are assessed, as well as whether high temporal or regional resolution is required given 120 
the extra effort to attain information to that level. The data sources and methods to use OTC 121 
sales data identified in this paper can be used in many countries globally, including countries 122 
where OTC sales data are not tracked by government agencies and could be used as an 123 
alternative data source to government data in countries in which it is tracked. In addition, two 124 
of the substances investigated are currently of high relevance to the EU commission. 125 
  126 
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2. METHODS 127 
Monthly prescription data for ibuprofen, diclofenac and ranitidine were obtained via 128 
subscription, covering a 12-month period from April 2016 – March 2017, from the IQVIA 129 
Prescription Service. IQVIA are an American multinational company serving industries of 130 
health information technologies and clinical research. In the UK, they work with 131 
pharmaceutical companies and the majority of NHS Trusts.36 Weekly OTC sales for all 132 
products in the UK containing ibuprofen, diclofenac and ranitidine covering the same period 133 
were obtained via subscription from Nielsen Holdings, an American global information data 134 
and measurements company who specialises in providing data on consumer goods.37 135 
 2.1 IMS (IQVIA) Prescription Data  136 
The data obtained from IQVIA contained monthly post code level information on the number 137 
of ‘sales’ of an individual product per postcode in the UK (excluding Ireland). In some cases, 138 
only the National Health Service (NHS) authority area was given. In these cases, a Google 139 
search of the entire authority name + post code gave a list of postcodes within that authorities’ 140 
area. An online document was provided with the data providing the definitions of the 141 
nomenclature (Health and Social Care Information Centre (HSCIC)).38 The British National 142 
Formulary (BNF)39 name of each product gave information on the active ingredient and the 143 
mass of the API per tablet or per dose in millilitres (this was converted to mg.ml-1). The 144 
milligram per tablet and milligram per millilitre values were multiplied by the ‘quantity’ value 145 
given in the data. The quantity value given was equal to the number of tablets or millilitres sold 146 
(as defined by HSCIC). The resultant value was divided by 1,000,000 to give the amount of 147 
API in kilograms per month per postcode. 148 
In a number of cases the BNF name contained a brand instead of the name of the API. To 149 
identify the products containing the APIs of interest (ibuprofen, diclofenac or ranitidine), a 150 
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search of each product was performed using the electronic Medicines Compendium (eMC)40 151 
website which contains up to date, easily accessible information about medicines licensed for 152 
use in the UK. Products not containing one of the three APIs were removed from the data. 153 
2.2 Nielsen Over the Counter Sales  154 
The data obtained from Nielsen were treated in a similar fashion to the prescription data. The 155 
same method as above was repeated to isolate products containing APIs of interest (ibuprofen, 156 
diclofenac or ranitidine). As well as identifying the API, a search of the eMC database was 157 
necessary to identify the mass of API in the specific products as this information was not given 158 
in the dataset. Only some of the products were present within the eMC database, a combination 159 
of other checks was used to confirm the amount of API per sale. Firstly, manufacturer’s 160 
websites product information pages were checked to confirm dosage. In some cases, products 161 
were not present on manufacturer’s current product range pages, presumably because that 162 
particular product had been discontinued. In these cases, a Google search of the product name 163 
or barcode given in the Nielsen dataset was performed and the API strength for products 164 
appearing for sale within the UK with an exact name or barcode match were added to the 165 
Nielsen data. On occasion bar codes were essential, for example, one brand of product 166 
containing ibuprofen had the same range of pack sizes for both 200 mg and 400 mg strength 167 
tablets, it was not clear from the name which strength tablets corresponded to which sales data. 168 
In this case the bar code information allowed confirmation and correct matching of API 169 
strength with sales data.  170 
The product strength was multiplied by the pack size (number of tablets, mls or grams). The 171 
total API per pack was converted to kg and multiplied by the unit sales per week per product 172 
to get the mass of API sold that week. 173 
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The Nielsen data are comprehensive, although there are some limitations. Nielsen obtain sales 174 
data from collaborators and non-collaborators. Larger collaborators (86% of total coverage), 175 
provide census information on sales, providing every sale, every week for every store. Smaller 176 
collaborators provide every sale, every week for some stores, this representative sample is 177 
extrapolated for non-contributing stores appropriately. Smaller collaborators and non-178 
collaborators (for which data are projected from larger collaborators) make up 14% of total 179 
coverage. This introduces some error into the OTC data which is not easily quantified. 180 
2.3 Combining Mass Data for comparison with CIP2 data 181 
The OTC and prescription data sets differed in their granularity with respect to time and 182 
location. The Nielsen data were recorded weekly compared with the prescription data being 183 
monthly. For location, the prescription data were recorded to post code level, whereas Nielsen 184 
data were available for larger defined regions: England & Wales, Central, East of England, 185 
Lancashire and English Border, London, North East, South & South East, South West, Wales 186 
& West, and Yorkshire. To combine the data spatially, the postcodes making up each region 187 
as defined by Nielsen were obtained with the rest of the Nielsen data. The relevant prescription 188 
data for those postcodes was pulled from the larger prescription datasets for each region 189 
investigated and the total kg per region was calculated. 190 
Prescription, OTC and CIP data were also not temporally aligned. For instance, the prescription 191 
data were measured from the 1st to the last of each month, the OTC data were given at seven-192 
day intervals, which did not align with the beginning and end of each month, the CIP data were 193 
obtained at irregular time points across the months. To allow the combining of the OTC and 194 
prescription data and subsequent comparison with the CIP data, totals were obtained for each 195 
time period, per month for prescription and per week for OTC. The weekly totals for the OTC 196 
data were then divided by seven allowing this data to then be matched with each month of the 197 
10 
 
prescription data i.e. weeks that crossed monthly boundaries were split and added to the 198 
relevant month. 199 
Data were totalled before and after being transformed by absorption and metabolism data. This 200 
exercise resulted in totals for each API for each region per month and per year in addition to 201 
England and Wales. Subdivisions of the totals were calculated so the contribution of each sub-202 
type could be accounted for e.g. OTC topical vs prescription topical. 203 
2.4 Calculating per person usage and release 204 
To calculate region-specific per capita prescription and OTC consumption, we obtained 205 
population data from the UK Office for National Statistics website.41 We aggregated these 206 
population counts to the level of Nielsen regions, based on the main post code areas included 207 
in them, as defined by the first two letters and number.42 Because population data were not 208 
available at the same resolution, some minor errors might have been introduced. For example, 209 
Breckland is made up of postcodes IP24, IP25 and IP26. IP24 and IP25 are included in the 210 
‘East of England’ Nielsen region, however IP26 falls within the ‘Yorkshire’ Nielsen region. 211 
Since the population information for these specific areas was not broken out these were simply 212 
included in the prevailing region, in this case 'East of England'. There were six of these 213 
incidences overall and the error contribution was not found to be large, for example, the total 214 
population of Breckland is 137,032, assuming equal distribution across post codes, 215 
approximately one third is assigned to the incorrect region (<0.08 % of the UK population). 216 
Monthly and yearly per person release rates were calculated for each region and England and 217 
Wales and temporal and regional release patterns were statistically compared.  218 
2.5 Calculating actual masses released after adsorption, metabolism and excretion 219 
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Once the total amounts of prescription and sales data had been tallied, we accounted for the 220 
amount of parent API excreted. The amount of API excreted after metabolism was the key 221 
factor for products taken orally and was relevant for ibuprofen, diclofenac and ranitidine. 222 
Ibuprofen and diclofenac were also found in many topically applied products, here there were 223 
two pathways to wastewater to consider. First, API absorbed through the skin, metabolised and 224 
excreted like the orally taken form and second, API not absorbed or metabolised (as shown in 225 
eq 1).  226 
(1)                            𝐸𝑡 = 𝑀𝑡. 𝑓𝑎 . 𝑓𝑚𝑒𝑡 +  𝑀𝑡. (1 − 𝑓𝑎) 227 
where 𝐸𝑡 is the emission to wastewater for a topical product; 𝑀𝑡  is the mass of API in the 228 
topical product; 𝑓𝑎 is the absorption of the topical product and 𝑓𝑚𝑒𝑡 is the fraction of the parent 229 
API released after metabolism. 230 
We assumed that 100% of the product that is not absorbed is released to wastewater. After 231 
product use, we assumed that consumers will wash the remaining product off using water in a 232 
sink as per the usage instructions. Product not fully absorbed into the skin will be transferred 233 
to clothes or bedding and will be subsequently washed. Whilst it is possible a consumer may 234 
use tissue paper to remove excess product and dispose via solid waste streams, we anticipated 235 
that most will wash hands due to the medicinal nature of the product and attempt to avoid 236 
applying gel to other parts of the body accidentally (as per the usage instructions). Some of the 237 
applied product may enter the environment via skin cell turnover, and we assumed that the 238 
majority of skin cells with product on or in them will be lost either whilst wearing clothes, 239 
washing or sleeping (with subsequent washing of clothes and bedding). Additionally, any 240 
remaining on the skin at the site of application that is not adsorbed into clothing or bedding is 241 
likely to be lost when bathing or showering.34 242 
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Ibuprofen undergoes significant metabolism in humans and is predominantly excreted via urine 243 
(~99%).43,44 Data identified for the excretion of ibuprofen from human urine, as conjugate and 244 
free, is presented in the supplementary information (SI table 1). Due to the wide range of values 245 
found in the literature, we used the median value of 10.7% as the fraction of free and conjugated 246 
ibuprofen excreted. A number of studies in the literature show that it is necessary to consider 247 
releases of the conjugates as it appears that these may be readily converted back to the parent 248 
molecule in the environment or waste water treatment process via hydrolysation or enzymes 249 
present in treatment plants.22,45–47  250 
A number of studies have investigated the bioavailability of topically applied ibuprofen 251 
compared with the orally taken drug, both in vivo and in vitro. Most studies performed in this 252 
area were not focussed on skin kinetics and do not provide clarity on the total mass of the active 253 
ingredient entering the body. Instead, the focus was on the amount of ibuprofen systemically 254 
bioavailable in the blood plasma as a percentage of what is available via the oral route. These 255 
studies do not factor in the importance of skin pharmacokinetics, including the ability of skin 256 
metabolism to affect how topically applied drugs enter the body as discussed by Nair et al. 257 
(2013).43,48–50 Hadgraft, Whitefield, and Rosher (2003)51 provide values more suitable for use 258 
in this work; they performed in vitro testing on six different types of formulations including 259 
gels, providing percentage values for the amount of applied active ingredient passing into and 260 
through the skin. The data are summarised in the supplementary information in SI Table 2 and 261 
show that the form of delivery is a key factor in the total absorption. We found that there were 262 
only three variations of gel formulation in the data sold under different brands. Absorption 263 
percentages (4.27-25.22%) were assigned based on the Hadgraft, Whitefield, and Rosher 264 
(2003)51 data.  265 
Diclofenac is metabolised to a large extent before excretion. According to Davies and 266 
Anderson (1997)52, approximately 2% is excreted unchanged in urine, whilst diclofenac only 267 
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leaves the body via the faeces after it has been metabolised. We assumed that anything in faeces 268 
does not contribute to the influent concentrations measured during the CIP project (samples 269 
were filtered and only the dissolved fraction measured). Thus, the value for urine excretion is 270 
used, along with the percentage absorbed topically, to calculate the total diclofenac being 271 
excreted into the environment. Two recently published studies give conflicting results on the 272 
absorption of different diclofenac formulations through the skin ex vivo. Haltner‐Ukomadu et 273 
al. (2019)53 give absorptions between 12.5 to 35.1% using parafilm occlusion, known to 274 
enhance absorption. Pradal et al. (2019)54 found relatively low values in comparison, with 275 
absorption fractions between 0.077% and 0.54% for two of the same formulations with no 276 
occlusion, but over a shorter time period. Both studies compared the rate of absorption between 277 
emulsion and hydrogel diclofenac formulations. The eMC website contains regulated and 278 
approved information on medicines available in the UK40, information on pharmacokinetics is 279 
given by pharmaceutical companies in ‘Summaries of Product Characteristics’. The total 280 
absorption value given for the most representative diclofenac formulation is 6%, which appears 281 
to be based on Reiss et al. (1986)55–57. This value is used for the absorption of topical diclofenac 282 
in this study due to both the extreme variation in the more recent studies, and its publication 283 
by eMC.  284 
Ranitidine is an orally taken drug, therefore only the excretion of unchanged drug is of interest 285 
in this study. Kortejärvi et al. (2005)58 summarise the literature on the pharmacokinetics of 286 
ranitidine, concluding between 25 - 30% can be excreted as unchanged drug. A conservative 287 
value of 30% has been used in calculating the release to wastewater of the total mass of 288 
ranitidine used. 289 
2.6 Chemical Investigations Programme (CIP1-C2) Data 290 
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Comber et al. (2018)11 provides great detail on the methods and their reliability pertaining to 291 
the data generated during the CIP 2 project. Briefly, samples were collected by 292 
stratified/random spot sampling with sampling at approximately monthly intervals. A 293 
minimum of 15% of samples were taken during non-working hours (evenings and weekends) 294 
to ensure coverage of variation occurring during the day. The samples were filtered, collected 295 
in stainless steel samplers, stored in glass containers and transported at 4 °C to the analysis 296 
laboratories. The samples were stored a maximum of 5 days prior to analysis. All analysis was 297 
by laboratories with ISO17025 accreditation. Methods used for the determination of 298 
pharmaceuticals were all based on variants of High Performance Liquid Chromatograph–Mass 299 
Spectrometry or Gas Chromatography-Mass Spectrometry.11 300 
Under the CIP scheme, not all WWTPs were measured over the same time period. OTC sales 301 
data could only be obtained back to the beginning of 2016, therefore, WWTPs with influent 302 
measurements taken throughout 2016-2017 were selected for this study. A range of plant sizes 303 
were selected with generated loads ranging from 7,901 to 168,863 population equivalent (PE). 304 
For confidentiality purposes, the names of the plants are not given. However, relevant details 305 
are provided in the results section. 306 
Measurements of influent concentrations were taken throughout the year, in some cases 307 
multiple measurements were taken in a month, whilst others may have had one or none. 308 
Multiple values were taken in 63% of the months measured. To allow comparison with the 309 
monthly API mass data, means and standard deviations were calculated for months with 310 
multiple measurements and used in the comparisons for each plant. For comparison with yearly 311 
totals, the mean concentration and standard deviation across the year was calculated for each 312 
plant. Using Tukey’s IQR method a number of extreme outliers were removed from the influent 313 
measurements, detailed information on this process and values removed can be found in the 314 
supplementary information under ‘Anomaly removal’. 315 
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2.7 Comparing total mass released with influent data 316 
Within the EU, a per capita wastewater contribution of 200 l.d-1 is recommended in ECHA 317 
guidance59,60. Greater amounts of water entering WWTPs will result in lower API 318 
concentrations, which will be further diluted in surface waters. The default of 200 l.d-1 is likely 319 
on the high side for the UK, a lower value of 150 l.d-1 has been previously suggested as an 320 
average per capita usage7. A more recent in depth analysis of water usage was conducted across 321 
the UK by DiscoverWater.co.uk, a grouping together of multiple bodies concerned with water 322 
management within the UK including amongst others, Water UK, Ofwat, and the Environment 323 
agency61. This website shows up to date information on UK water usage, however data for 324 
previous years is better presented elsewhere. Love2Laundry.com has linked to and displays 325 
more detailed information from the Discoverwater dataset, including historic data from 326 
previous years. Data include water usage across the different regions as well as the average 327 
yearly per capita water usage across the whole UK which was 141 l.d-1 in 2016-1762. This value 328 
is significantly lower than defaults assumed in EU guidance. Influent water flows may contain 329 
contributions from runoff and industry, however it was difficult to account for these in a 330 
meaningful way based on the data available. In an effort to highlight or make visible how any 331 
industry contribution might affect the data, WWTPs were selected from urban (presumed to 332 
have industrial inputs), suburban and rural (presumed to have low or no industrial inputs) 333 
settings. The assumption that those in suburban and rural settings would have minimal 334 
industrial input (if any) was deemed reasonable based on inspection of these areas using 335 
GoogleTM Maps. It was assumed that there is no API in runoff or manufactured in industry near 336 
the plants selected although it is acknowledged that the dilution is a significant source of 337 
variability in this work.  338 
To allow a comparison of the mass of each API released with the influent data, we performed 339 
the following actions. To obtain an expected mass heading to a specific WWTP, the regional 340 
16 
 
per person per month mass was multiplied by the PE (as a proxy for the population served) of 341 
the respective WWTP. The influent concentration data was transformed to a mass by 342 
multiplying the average UK water usage per person per day by the PE to account for dilution, 343 
the previously discussed value of 141 l.p-1.d-1 was used in this calculation. The use of a constant 344 
dilution is a significant source of error, however data on flow that coincide with the measured 345 
influent concentrations were not available. Regression analysis was performed on monthly 346 
predictions to assess how well the expected mass released predicted the actual mass in the 347 
influent. 348 
2.8 Statistical Analysis 349 
Using Tukey’s IQR method a number of extreme outliers were removed from the influent 350 
measurements, detailed information on this process and values removed can be found in the 351 
supplementary information under ‘Anomaly removal’. 352 
One-way ANOVA was performed to look for statistical differences across the months and 353 
across the regions for each the per capita release of each API. Where a statistical difference 354 
was found a post hoc Tukey test was performed. 355 
Data processing was performed in Microsoft Excel 2016 with more detailed statistical analysis 356 
being performed in JASP (version 0.11.1).  357 
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3. RESULTS AND DISCUSSION 358 
3.1 Contribution of prescription, OTC, oral and topical consumption to regional use 359 
The total mass of each API sold or prescribed in 2016-17 can be found in Table 1. For ibuprofen 360 
and diclofenac, OTC sales make up a significant portion of the total mass of API used by the 361 
populace per year. This is most significant for ibuprofen, where OTC sales make up 76.16% 362 
of the total mass. Prescriptions are more important for ranitidine, with just 4.88% of the total 363 
mass coming from OTC sales. With regards to OTC sales, orally taken forms of ibuprofen 364 
made up a significantly higher portion of the total mass in 2016 at 98.13%. This was in contrast 365 
to diclofenac where the mass contributed from topical OTC sales was nearly 99.99%. The sale 366 
of oral diclofenac OTC was actually banned in the UK in January 201563, the small amount of 367 
sales data showing oral OTC sales is therefore likely an artefact introduced by the information 368 
gathering techniques used by Nielsen described in the methods section. Combining prescription 369 
and OTC data, topical applications of ibuprofen made up 7.9% of the total mass in 2016. 370 
Diclofenac topical applications were more significant with 63.1% of the mass contribution, 371 
when considering prescription and OTC uses.  372 
Overall, 409.5 tonnes of ibuprofen, 44 tonnes of ranitidine and 8.5 tonnes of diclofenac were 373 
released to the UK public through prescriptions and OTC sales in 2016. SI Table 3 shows the 374 
mass of API used per capita in each region across England and Wales in detail. The data 375 
demonstrate that regional preferences for self-medication (with respect to pain relief and heart 376 
burn) vary. For example, the OTC per person usage of ibuprofen is higher in the 'London' and 377 
'South & South East' regions when compared with the average across England and Wales. 378 
However, the amount prescribed is lower than the average across England and Wales. This is 379 
in contrast to the 'North East' region, where total usage is fairly representative of England and 380 
Wales as a whole. However, in this region the prescription rates per person are higher than the 381 
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average across England and Wales with OTC sales being lower than average when compared 382 
with England and Wales. Similar patterns can be observed across the data for both diclofenac 383 
and ranitidine. 384 
Table 1. Total mass of each API sold OTC or prescribed from 01/04/2016 to 31/03/2017 in 385 
England and Wales 386 
3.2 Wastewater releases of prescription, OTC, oral and topical APIs 387 
Table 2 displays the totals for each API released to wastewater, calculated after topical 388 
absorption (where applicable) and metabolism. For both diclofenac and ibuprofen, OTC 389 
contributions make up over 50% of the API mass released. As can be seen from these data, a 390 
significant proportion of API mass comes from OTC sales. In agreement with previous work, 391 
depending on the API, not accounting for contributions from OTC sales could lead to 392 
significant underprediction of exposure when comparing with MECs.22  393 
The large releases from OTC diclofenac (where prescription usage accounts for a larger portion 394 
of the mass being used) is explained by the relative contributions of topical and oral 395 
applications. OTC sales for diclofenac are nearly all attributable to topical application. Based 396 
on absorption and release percentages, 1.99% of the oral mass of diclofenac used is released to 397 
wastewater compared with 94.1% of the topical mass used. It is a similar story for ibuprofen, 398 
94.4% of the total topical mass used is released to wastewater compared with 10.7% of the 399 
orally taken drug. This means that despite the use of orally taken ibuprofen being over 10-fold 400 
greater (376,996 vs 32,465 kg year-1), the amount released to the environment is less than 1.5-401 
fold greater (40,338 vs 30,643 kg year-1). These values are of course subject to the assumptions 402 
that any unabsorbed API is emitted to wastewater for topical applications. This assumption is 403 
discussed in the methods section and is based on previous work on so-called secondary routes 404 
of environmental exposure in Daughton et al. (2009).34 Here it is shown that topical 405 
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applications contribute a disproportionally high environmental loading and are clearly an 406 
important source of releases to wastewater for certain APIs. Depending on skin absorption, 407 
topical applications have the potential to contribute much greater quantities per unit mass used 408 
compared with oral because the unabsorbed fraction is not metabolised. Steps to mitigate 409 
environmental loadings of topically applied APIs have previously been discussed by Daughton 410 
and Ruhoy (2009),34 who suggest a number of pollution reducing measures for topical 411 
applications, including providing absorbent wipes to remove excess product after application, 412 
or the development of more accurate dispensers preventing wastage. Recent trends for 413 
ibuprofen products include topical patches, with any remaining unabsorbed API left in the 414 
patch to be discarded in the solid waste stream. These might be a more environmentally friendly 415 
alternative to topical gels for similar reasons. It is clear that exposure estimates of APIs can be 416 
improved by incorporating OTC consumption but that it is equally important to consider 417 
product format and all routes of exposure beyond oral prescription when assessing the 418 
environmental exposure of APIs. The contribution of each route of exposure and acquisition is 419 
key in a regulatory context. Where APIs become priority substances under the WFD, EU 420 
member states have a legal obligation to comply with set EQS values and where these are not 421 
met, must take action to reduce environmental concentrations. Identifying contributing factors 422 
and balancing them with human benefits is a key consideration. 423 
Table 2. Total mass of API released to the environment after absorption and metabolism from 424 
01/04/2016 to 31/03/2017 425 
3.3 Variation in regional and temporal releases 426 
Monthly and annual per capita release rates after absorption and metabolism are shown in SI 427 
Table 4, for each API at both the national level (England & Wales) and at the level of individual 428 
regions. The per capita usage for England and Wales was calculated by dividing up the total 429 
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mass by population, rather than being a mean of the other per capita values. One-way ANOVA 430 
was performed to look for statistical differences across the months and across the regions for 431 
each API. No statistical differences were found between the monthly release rates. A statistical 432 
difference was found between the regional releases so a post hoc Tukey test was performed. 433 
Most regions were statistically different from each other (statistically different regions can be 434 
viewed in SI table 4). A large variation was found between regions, the range in yearly per 435 
capita usage, as a percentage of the national per capita use, was 43% for ibuprofen, 50% for 436 
diclofenac and 76% for ranitidine. For ibuprofen, the ‘North East’, ‘South West’, ‘Wales & 437 
West’ and ‘Yorkshire’ were all significantly different to the national per capita usage of 438 
‘England and Wales’. A lower number of regions were considered statistically similar to the 439 
national region for the other two APIs. Only the ‘Central’, ‘London’, ‘South and South East’ 440 
and ‘South West’ were statistically similar to national usage for diclofenac, and only ‘South 441 
and South East’ and ‘South West’ regions were similar for ranitidine. 442 
It is difficult to explain or postulate the reasons for the large differences between regions in the 443 
context of this study alone. These numbers could be indicative of the overall health of a region, 444 
linked to age demographics or could be down to differences in the culture relating to self-care 445 
or medicine use. An analysis of the data against other epidemiological data might help to shed 446 
light on these differences. For the purposes of this study, it can be concluded that using a per 447 
capita use rate for a whole country in a region or site-specific exposure assessment could 448 
introduce significant error in any modelling exercise as suggested by He et al. (2020).31 There 449 
is a clear benefit to using region-specific use data where possible as shown by the statistically 450 
significant differences between a number of regions when compared with the total per capita 451 
usage for the ‘England and Wales’ national region.  452 
3.4 Comparison of mass released with mass in influent 453 
21 
 
The influent masses of all three APIs, back-calculated from the influent concentrations 454 
measured, are predicted reasonably well by the mass released, as calculated from sales and 455 
prescription data (Figure 1). However, there is a consistent overestimation of the mass in 456 
influent for all three APIs. This overestimation is greater for diclofenac, for which a larger 457 
proportion of values fall outside of the two-fold and five-fold lines. The factor differences 458 
between the expected mass and the mass in influent for each API can be seen in the 459 
supplementary information. For ibuprofen, the median factor difference was 1.46 with a 95th 460 
percentile value of 3.63. The median factor difference for diclofenac was 3.16 with a 95th 461 
percentile of 12.14, and for ranitidine the values were 2.03 and 5.69 respectively.  462 
Whilst there might be multiple factors leading to the overestimation of the influent mass, it is 463 
common to all three APIs and appears to be independent of API format or route of acquisition 464 
and the size or location type of the WWTPs. It was expected that the urban WWTPs included 465 
in the study might have significant industrial wastewater contributions which would lead to a 466 
greater overestimation of influent mass relative to the suburban and rural WWTPs, however no 467 
clear patterns are visible across the data suggesting that the industrial inputs are either not as 468 
high as anticipated for the urban WWTPs, or contribute wastewater that is of similar structure 469 
to that produced by resident populations and is therefore taken into account in the PE capacity 470 
of each WWTP (which is calculated based on an assumed BOD load per person). Overall this 471 
suggests an additional factor needs to be considered when predicting influent concentrations. 472 
Multiple studies have identified that a significant amount of removal via biodegradation and 473 
other processes can occur during sewer transport.20,21 To assess whether in-sewer removal 474 
could reasonably explain the overestimation for each API, the mean overestimation of the 475 
influent mass was divided by a range of sewer retention times (one to six hours) to give a range 476 
of hypothetical in-sewer removal rates. These removal rates were compared to WWTP removal 477 
rates identified in recent literature.12,13 Theoretical removal rates appear within reason for 478 
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ibuprofen (0.05 - 0.32 h-1 compared to 0.15 – 1.5 h-1), however the theoretical levels of in-479 
sewer removal for diclofenac (0.1 – 0.62 h-1 compared to 0 – 0.1 h-1) and ranitidine (0.08 – 0.49 480 
h-1 compared to 0.09 h-1) were only realistic for the longest theoretical sewer residence time of 481 
six hours.   482 
Whilst the literature supports the hypothesis that in-sewer removal is contributing to the over 483 
estimation of influent mass, other factors appear to be playing a role, particularly for diclofenac 484 
and ranitidine. Bound et al. (2005)64 performed a survey in England finding that just over 50% 485 
of respondents finished their medication, a third kept their pharmaceuticals until the expiration 486 
date (disposing of the left-overs at that point), with the remainder disposing of their 487 
pharmaceuticals once treatment was complete. Approximately 70% of respondents disposed of 488 
used pharmaceuticals via the solid waste stream. Some of the variation could be accounted for 489 
by differences in how consumers use OTC vs prescription drugs with presumably less variation 490 
in the correct amount of drug being prescribed by doctors, and patient conformity to taking the 491 
full course of treatment. Another factor might be the method of delivery, for example, there are 492 
less variety in pack sizes for topical applications compared with oral, potentially leading to 493 
more frequent over-prescribing or purchasing. Topical application makes up a larger proportion 494 
of use for diclofenac, therefore an over assumption in the amount of API washed off might 495 
cause a larger overestimation of API release compared to ibuprofen.  Repeating this exercise 496 
with oral and prescription only APIs measured in the CIP influent data might eliminate a 497 
significant proportion of the variability and could allow reasonably accurate sewer removal 498 
rates for APIs to be derived. However, Johnson et al. (2004)15 have demonstrated that 499 
accounting for the in-sewer removal of different API metabolites is complex. There is limited 500 
data collected on APIs or other chemicals in this regard. 501 
Figure 1. Scatter plot with a logarithmic scale (base 10) comparing absolute values of the 502 
total daily mass of ibuprofen, diclofenac and ranitidine released to the sewer (x-axis) with the 503 
23 
 
back calculated mass measured in influent (y-axis) across all WWTPs. Lines show 0, 2- and 504 
5-fold differences. Each point represents the comparison of a measured and predicted influent 505 
value. 506 
 507 
3.5 Influence of sewer retention time 508 
As the mass calculation for release is the per capita use rate multiplied by the PE of each 509 
WWTP and the influent mass is calculated using the per capita dilution, normalised per capita 510 
residual plots were made to identify any trends in the overestimation of the influent mass as 511 
plant size increases (residual plots can be found in the supplementary information SI figures 1-512 
6). Figure 1 (in addition to SI Figure 1-3) shows that for each API, there is no increasing over 513 
estimation, and therefore in-sewer removal, as plant size increases. This is in contrast to Kapo 514 
et al. (2017)20 who suggest median sewer residence times differ based on treatment facility size 515 
in the USA. Other data in the literature indicate that sewer retention time does not necessarily 516 
follow a predictable pattern. Holt et al. (1998)65 quote a mean measured sewer retention time 517 
of two hours based on six WWTPs in Yorkshire (UK), although no explanation is given on 518 
where this value came from (e.g. whether it was obtained by company survey). A survey of 519 
wastewater treatment plant operators across Europe by Ort et al. (2014)66 gives a median sewer 520 
retention time of approximately four hours.20 The residence times were provided in response 521 
to a questionnaire given to WWTP managers, the approaches with which the surveyed 522 
treatment plants determined their sewer residence time in each case are unfortunately not 523 
stated.66 During the work performed here a short exercise was performed to assess whether the 524 
median sewer residence times defined in Kapo et al. (2017) were able to predict the sewer 525 
residence times given in Ort et al. (2014)66 based on the design capacity and population served 526 
census data given in their supplementary information. Residence times were assigned based on 527 
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the plant capacity and plotted against the residence times given in the survey, a poor 528 
relationship was observed (R2 = 0.057). The census population and design capacity were also 529 
plotted against the residence times, however poor relationships (R2 = 0.059 and 0.06 530 
respectively) were observed here too. These data indicate that it may be necessary to assess 531 
sewer retention time on an individual site basis, or that other factors may need consideration, 532 
such as when and how the sewer system was designed and built. Whilst sewer retention time 533 
may not vary in a predictable way, the data here appear to agree with recent literature 534 
suggesting that in-sewer removal should be considered in exposure modelling exercises, 535 
however further study is required to separate the amount of in-sewer removal from other 536 
sources of overestimation.  537 
3.6 Conclusions 538 
The results show that OTC sales and topical product formats can contribute significantly to the 539 
mass of APIs released to wastewater with topical formats contributing more per unit mass used 540 
than oral formats (for the APIs included here). This is of great significance to the current 541 
science surrounding the environmental risk assessment of pharmaceuticals given the lack of 542 
consideration previously given to topical formats and their emissions. Exposure estimates of 543 
APIs clearly need to incorporate all routes of acquisition and product format types to be truly 544 
representative of the API under consideration. In addition to improving exposure science, these 545 
findings are of regulatory importance with regards to the future assessment of APIs which end 546 
up being regulated under the WFD and the subsequent legal obligation EU member states will 547 
have in complying with EQS values.  548 
Significant regional differences in API per capita usage were found, although no significant 549 
month to month temporal variation was observed. It is therefore concluded that assessing the 550 
exposure of an API using a per capita use rate for a whole country could introduce significant 551 
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error at the region or site-specific level and there is a clear benefit to using region-specific use 552 
data where possible. 553 
Mass to wastewater releases were predicted well when compared with the mass in influent back 554 
calculated from the CIP data. A consistent overestimation of the mass in influent was observed, 555 
however. The overestimation was attributed to a number of potential factors, including 556 
consumer habits e.g. not using all of the medication purchased, assumptions made in mass 557 
calculations and in-sewer removal, however further work to assess the importance of each 558 
factor is recommended and is required to increase the accuracy of environmental exposure 559 
assessments for APIs. 560 
The study provides methods for incorporating OTC API data into environmental exposure 561 
assessments that can be used in a wide range of countries. Nielsen gather data globally, in 100+ 562 
countries, the methods used herein are therefore applicable to any country where government 563 
agencies do not gather data on OTC sales (such as the UK and many others) and could allow 564 
for the incorporation of OTC data more widely. The authors encourage the use of the methods 565 
detailed herein to investigate the OTC contribution of other APIs where this data is available. 566 
 567 
Supporting information. One excel file is provided as supplementary information containing; 568 
SI tables 1-4, anomaly removal method description, volume data on ibuprofen, diclofenac and 569 
ranitidine. 570 
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